1. Home
  2. ES vs BIIB Comparison

ES vs BIIB Comparison

Compare ES & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eversource Energy (D/B/A)

ES

Eversource Energy (D/B/A)

HOLD

Current Price

$65.95

Market Cap

27.7B

Sector

Utilities

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$174.80

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ES
BIIB
Founded
1927
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.7B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
ES
BIIB
Price
$65.95
$174.80
Analyst Decision
Hold
Buy
Analyst Count
12
22
Target Price
$70.83
$177.40
AVG Volume (30 Days)
2.7M
2.7M
Earning Date
02-10-2026
02-11-2026
Dividend Yield
4.48%
N/A
EPS Growth
N/A
N/A
EPS
3.65
10.97
Revenue
$13,148,536,000.00
$10,065,900,000.00
Revenue This Year
$10.10
$3.61
Revenue Next Year
$4.11
N/A
P/E Ratio
$18.42
$15.93
Revenue Growth
13.12
4.77
52 Week Low
$52.28
$110.04
52 Week High
$75.25
$185.17

Technical Indicators

Market Signals
Indicator
ES
BIIB
Relative Strength Index (RSI) 38.86 54.75
Support Level $66.73 $168.56
Resistance Level $68.18 $175.94
Average True Range (ATR) 1.23 5.10
MACD 0.14 -1.52
Stochastic Oscillator 38.98 42.10

Price Performance

Historical Comparison
ES
BIIB

About ES Eversource Energy (D/B/A)

Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric and gas distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. The company exited most of its unregulated businesses in 2006.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: